695 related articles for article (PubMed ID: 26580307)
1. Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
Lam RW; Levitt AJ; Levitan RD; Michalak EE; Cheung AH; Morehouse R; Ramasubbu R; Yatham LN; Tam EM
JAMA Psychiatry; 2016 Jan; 73(1):56-63. PubMed ID: 26580307
[TBL] [Abstract][Full Text] [Related]
2. Appetitive Symptoms Differentially Predict Treatment Response to Fluoxetine, Light, and Placebo in Nonseasonal Major Depression.
Levitan RD; Levitt AJ; Michalak EE; Morehouse R; Ramasubbu R; Yatham LN; Tam EM; Lam RW
J Clin Psychiatry; 2018 Jul; 79(4):. PubMed ID: 30063303
[TBL] [Abstract][Full Text] [Related]
3. Novel Augmentation Strategies in Major Depression.
Martiny K
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.
Quiroz JA; Tamburri P; Deptula D; Banken L; Beyer U; Rabbia M; Parkar N; Fontoura P; Santarelli L
JAMA Psychiatry; 2016 Jul; 73(7):675-84. PubMed ID: 27304433
[TBL] [Abstract][Full Text] [Related]
5. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
6. Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
Richards C; McIntyre RS; Weisler R; Sambunaris A; Brawman-Mintzer O; Gao J; Geibel B; Dauphin M; Madhoo M
J Affect Disord; 2016 Dec; 206():151-160. PubMed ID: 27474961
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, placebo-controlled study of light therapy for antepartum depression.
Wirz-Justice A; Bader A; Frisch U; Stieglitz RD; Alder J; Bitzer J; Hösli I; Jazbec S; Benedetti F; Terman M; Wisner KL; Riecher-Rössler A
J Clin Psychiatry; 2011 Jul; 72(7):986-93. PubMed ID: 21535997
[TBL] [Abstract][Full Text] [Related]
8. Comparison of venlafaxine alone versus venlafaxine plus bright light therapy combination for severe major depressive disorder.
Güzel Özdemir P; Boysan M; Smolensky MH; Selvi Y; Aydin A; Yilmaz E
J Clin Psychiatry; 2015 May; 76(5):e645-54. PubMed ID: 26035199
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.
Tohen M; Vieta E; Calabrese J; Ketter TA; Sachs G; Bowden C; Mitchell PB; Centorrino F; Risser R; Baker RW; Evans AR; Beymer K; Dube S; Tollefson GD; Breier A
Arch Gen Psychiatry; 2003 Nov; 60(11):1079-88. PubMed ID: 14609883
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study.
Montgomery SA; Mansuy L; Ruth A; Bose A; Li H; Li D
J Clin Psychiatry; 2013 Apr; 74(4):363-9. PubMed ID: 23656841
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.
Trivedi MH; Cutler AJ; Richards C; Lasser R; Geibel BB; Gao J; Sambunaris A; Patkar AA
J Clin Psychiatry; 2013 Aug; 74(8):802-9. PubMed ID: 24021497
[TBL] [Abstract][Full Text] [Related]
12. Bright light treatment in elderly patients with nonseasonal major depressive disorder: a randomized placebo-controlled trial.
Lieverse R; Van Someren EJ; Nielen MM; Uitdehaag BM; Smit JH; Hoogendijk WJ
Arch Gen Psychiatry; 2011 Jan; 68(1):61-70. PubMed ID: 21199966
[TBL] [Abstract][Full Text] [Related]
13. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis.
Benazzi F; Berk M; Frye MA; Wang W; Barraco A; Tohen M
J Clin Psychiatry; 2009 Oct; 70(10):1424-31. PubMed ID: 19906346
[TBL] [Abstract][Full Text] [Related]
14. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial.
Rickels K; Athanasiou M; Robinson DS; Gibertini M; Whalen H; Reed CR
J Clin Psychiatry; 2009 Mar; 70(3):326-33. PubMed ID: 19284933
[TBL] [Abstract][Full Text] [Related]
15. The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial.
Davey CG; Chanen AM; Hetrick SE; Cotton SM; Ratheesh A; Amminger GP; Koutsogiannis J; Phelan M; Mullen E; Harrison BJ; Rice S; Parker AG; Dean OM; Weller A; Kerr M; Quinn AL; Catania L; Kazantzis N; McGorry PD; Berk M
Lancet Psychiatry; 2019 Sep; 6(9):735-744. PubMed ID: 31371212
[TBL] [Abstract][Full Text] [Related]
16. Predictors and Moderators of Remission With Aripiprazole Augmentation in Treatment-Resistant Late-Life Depression: An Analysis of the IRL-GRey Randomized Clinical Trial.
Kaneriya SH; Robbins-Welty GA; Smagula SF; Karp JF; Butters MA; Lenze EJ; Mulsant BH; Blumberger D; Anderson SJ; Dew MA; Lotrich F; Aizenstein HJ; Diniz BS; Reynolds CF
JAMA Psychiatry; 2016 Apr; 73(4):329-36. PubMed ID: 26963689
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder.
Khan A; Cutler AJ; Kajdasz DK; Gallipoli S; Athanasiou M; Robinson DS; Whalen H; Reed CR
J Clin Psychiatry; 2011 Apr; 72(4):441-7. PubMed ID: 21527122
[TBL] [Abstract][Full Text] [Related]
18. The Can-SAD study: a randomized controlled trial of the effectiveness of light therapy and fluoxetine in patients with winter seasonal affective disorder.
Lam RW; Levitt AJ; Levitan RD; Enns MW; Morehouse R; Michalak EE; Tam EM
Am J Psychiatry; 2006 May; 163(5):805-12. PubMed ID: 16648320
[TBL] [Abstract][Full Text] [Related]
19. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
[TBL] [Abstract][Full Text] [Related]
20. A sham-controlled randomized trial of adjunctive light therapy for non-seasonal depression.
Chojnacka M; Antosik-Wójcińska AZ; Dominiak M; Bzinkowska D; Borzym A; Sokół-Szawłowska M; Bodzak-Opolska G; Antoniak D; Święcicki Ł
J Affect Disord; 2016 Oct; 203():1-8. PubMed ID: 27267951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
